Neeraj Agarwal - Concepedia

Author

Neeraj Agarwal

Vall d'Hebron Institute of Oncology ORCID

Also Known As

N. Agarwal, Neeraj Agarwal, Neeraj Kumar Agarwal

Publications

802

Citations

H-Index

Concepts

All Affiliations

Vall d'Hebron Institute of Oncology Vall d'Hebron Hospital Universitari University of Utah Huntsman Cancer Institute Peter MacCallum Cancer Centre

About

Neeraj Agarwal is an author at Vall d'Hebron Institute of Oncology specializing in medicine, urology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	63
2	Immunology	1	1	40
3	Nephrology	1	1	23
4	Pathology	1	1	23
5	Pharmacology	1	1	23

Neeraj Agarwal

Publications

717

Citations

H-Index

Page 1

	Year	Citations
Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer James L. Gulley, Michael Borre, Nicholas J. Vogelzang, Journal of Clinical Oncology	2019	263
Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5 Karim Fizazi, Robert J. Jones, Stéphane Oudard, Journal of Clinical Oncology	2015	151
Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer Mamta Parikh, Chengfei Liu, Chun‐Yi Wu, Scientific Reports	2021	83
Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer Neeraj Agarwal, Jean-Pascal Machiels, Cristina Suárez, The Oncologist	2016	76
Development of PROSTVAC Immunotherapy in Prostate Cancer Parminder Singh, Sumanta K. Pal, Anitha Alex, Future Oncology UrologyCancer ImmunosurveillanceMedicineImmunologyPhase Iii Trial	2015	40
A Phase III, Randomized, Open-Label Study (CONTACT-02) of Cabozantinib Plus Atezolizumab Versus Second Novel Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Neeraj Agarwal, Arun Azad, Joan Carles, Future Oncology	2022	36
Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial. Neeraj Agarwal, Arun Azad, Joan Carles, Journal of Clinical Oncology PathologyEnza 160PharmacotherapyLba18 BackgroundTranslational Medicine	2025	23
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial Neeraj Agarwal, Arun Azad, Joan Carles, The Lancet	2025	14
Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial Neeraj Agarwal, Arun Azad, Joan Carles, The Lancet Oncology	2025	11
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study Arun Azad, Karim Fizazi, Nobuaki Matsubara, European Journal of Cancer	2024	10

Page 1